Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers The data from the ongoing ...
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers The company's groundbreaking immunoliposome, containin ...
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss Preclinical results in naturally occurred diabetic monke ...
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates HFK1 is the company’s groundbreaking drug ...
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions Filing of a U.S. IND for HFG1 is ...
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting The company is developing next generation lipid-based structures that kill cancer cells and expose ca ...
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors HANGZHOU, China--January 8, 2024--HighField Biopharm ...
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers The company’s groundbreaking drug encapsulated immun ...
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma HighField CEO Yuhong Xu and CBO Donald Wyatt ...
HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancerHANGZHOU, CHINA--HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology co ...
English 
简体中文